A Disease Registry of Patients with Mantle Cell Lymphoma - SUMMIT

Study identifier:D8220R00004

ClinicalTrials.gov identifier:NCT03816683

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents

Medical condition

Mantle Cell Lymphoma

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

229

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 01 Apr 2019
Estimated Primary Completion Date: 30 Jun 2024
Estimated Study Completion Date: 30 Jun 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria